FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313305857> ?p ?o ?g. }

• W4313305857 endingPage "2487" @default.
• W4313305857 startingPage "2478" @default.
• W4313305857 abstract "A simplified protocol for regional citrate anticoagulation (RCA) using a commercial calcium-containing replacement solution, without continuous calcium infusion, is more efficient for use in continuous renal replacement therapy (CRRT). We aim to design a randomized clinical trial to compare the safety and efficacy between calcium-free and calcium-containing replacement solutions in CRRT with RCA.Of the 64 patients receiving RCA-based postdilution continuous venovenous hemodiafiltration (CVVHDF) enrolled from 2017 to 2019 in West China Hospital of Sichuan University, 35 patients were randomized to the calcium-containing group and 29 to the calcium-free replacement solution group. The primary endpoint was circuit lifespan and Kaplan-Meier survival analysis was performed. Secondary endpoints included hospital mortality, kidney function recovery rate, and complications. The amount of 4% trisodium citrate solution infusion was recorded. Serum and effluent total (tCa) and ionized (iCa) calcium concentrations were measured during CVVHDF.A total of 149 circuits (82 in the calcium-containing group and 67 in the calcium-free group) and 7609 circuit hours (4335 h vs. 3274 h) were included. The mean circuit lifespan was 58.1 h (95% CI 53.8-62.4 h) in the calcium-containing group vs. 55.3 h (95% CI 49.7-60.9 h, log rank P = 0.89) in the calcium-free group. The serum tCa and iCa concentrations were slightly lower in the calcium-containing group during CRRT, whereas the postfilter iCa concentration was lower in the calcium-free group. Moreover, the mean amounts of 4% trisodium citrate solution infusion were not significantly different between the groups (171.1 ± 15.9 mL/h vs. 169.0 ± 15.1 mL/h, P = 0.49). The mortality (14/35 [40%] vs. 13/29 [45%], P = 0.70) and kidney function recovery rates of AKI patients (19/26, 73% vs. 14/24, 58%, P = 0.27) were comparable between the calcium-containing and calcium-free group during hospitalization, respectively. Six (three in each group) patients showed signs of citrate accumulation in this study.When compared with calcium-free replacement solution, RCA-based CVVHDF with calcium-containing replacement solution had a similar circuit lifespan, hospital mortality and kidney outcome. Since the calcium-containing solution obviates the need for a separate venous catheter and a large dose of intravenous calcium solution preparation for continuous calcium supplementation, it is more convenient to be applied in RCA-CRRT practice.Chinese Clinical Trial Registry (www.chictr.org.cn, ChiCTR-IPR-17012629)." @default.
• W4313305857 created "2023-01-06" @default.
• W4313305857 creator A5002661071 @default.
• W4313305857 creator A5005080101 @default.
• W4313305857 creator A5006177282 @default.
• W4313305857 creator A5019429833 @default.
• W4313305857 creator A5023236133 @default.
• W4313305857 creator A5070324805 @default.
• W4313305857 creator A5083228843 @default.
• W4313305857 date "2022-10-20" @default.
• W4313305857 modified "2023-10-16" @default.
• W4313305857 title "Calcium-containing versus calcium-free replacement solution in regional citrate anticoagulation for continuous renal replacement therapy: a randomized controlled trial" @default.
• W4313305857 cites W1974164278 @default.
• W4313305857 cites W1996705186 @default.
• W4313305857 cites W2001529112 @default.
• W4313305857 cites W2010260789 @default.
• W4313305857 cites W2019511213 @default.
• W4313305857 cites W2021393753 @default.
• W4313305857 cites W2040394401 @default.
• W4313305857 cites W2066960549 @default.
• W4313305857 cites W2069091142 @default.
• W4313305857 cites W2076330369 @default.
• W4313305857 cites W2109172549 @default.
• W4313305857 cites W2112684338 @default.
• W4313305857 cites W2112900044 @default.
• W4313305857 cites W2167157956 @default.
• W4313305857 cites W2169985183 @default.
• W4313305857 cites W2317530004 @default.
• W4313305857 cites W2352105328 @default.
• W4313305857 cites W2555930185 @default.
• W4313305857 cites W2768801834 @default.
• W4313305857 cites W2912272600 @default.
• W4313305857 cites W2921177074 @default.
• W4313305857 cites W2947461022 @default.
• W4313305857 cites W3009355598 @default.
• W4313305857 cites W3043218379 @default.
• W4313305857 cites W3094020901 @default.
• W4313305857 cites W3125816219 @default.
• W4313305857 cites W3134929965 @default.
• W4313305857 cites W3145717665 @default.
• W4313305857 cites W3152270167 @default.
• W4313305857 cites W3189849686 @default.
• W4313305857 doi "https://doi.org/10.1097/cm9.0000000000002369" @default.
• W4313305857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36583864" @default.
• W4313305857 hasPublicationYear "2022" @default.
• W4313305857 type Work @default.
• W4313305857 citedByCount "3" @default.
• W4313305857 countsByYear W43133058572023 @default.
• W4313305857 crossrefType "journal-article" @default.
• W4313305857 hasAuthorship W4313305857A5002661071 @default.
• W4313305857 hasAuthorship W4313305857A5005080101 @default.
• W4313305857 hasAuthorship W4313305857A5006177282 @default.
• W4313305857 hasAuthorship W4313305857A5019429833 @default.
• W4313305857 hasAuthorship W4313305857A5023236133 @default.
• W4313305857 hasAuthorship W4313305857A5070324805 @default.
• W4313305857 hasAuthorship W4313305857A5083228843 @default.
• W4313305857 hasBestOaLocation W43133058571 @default.
• W4313305857 hasConcept C126322002 @default.
• W4313305857 hasConcept C126894567 @default.
• W4313305857 hasConcept C141071460 @default.
• W4313305857 hasConcept C168563851 @default.
• W4313305857 hasConcept C185592680 @default.
• W4313305857 hasConcept C2779541074 @default.
• W4313305857 hasConcept C2780400767 @default.
• W4313305857 hasConcept C42219234 @default.
• W4313305857 hasConcept C519063684 @default.
• W4313305857 hasConcept C55493867 @default.
• W4313305857 hasConcept C71924100 @default.
• W4313305857 hasConcept C87975464 @default.
• W4313305857 hasConceptScore W4313305857C126322002 @default.
• W4313305857 hasConceptScore W4313305857C126894567 @default.
• W4313305857 hasConceptScore W4313305857C141071460 @default.
• W4313305857 hasConceptScore W4313305857C168563851 @default.
• W4313305857 hasConceptScore W4313305857C185592680 @default.
• W4313305857 hasConceptScore W4313305857C2779541074 @default.
• W4313305857 hasConceptScore W4313305857C2780400767 @default.
• W4313305857 hasConceptScore W4313305857C42219234 @default.
• W4313305857 hasConceptScore W4313305857C519063684 @default.
• W4313305857 hasConceptScore W4313305857C55493867 @default.
• W4313305857 hasConceptScore W4313305857C71924100 @default.
• W4313305857 hasConceptScore W4313305857C87975464 @default.
• W4313305857 hasIssue "20" @default.
• W4313305857 hasLocation W43133058571 @default.
• W4313305857 hasLocation W43133058572 @default.
• W4313305857 hasLocation W43133058573 @default.
• W4313305857 hasLocation W43133058574 @default.
• W4313305857 hasOpenAccess W4313305857 @default.
• W4313305857 hasPrimaryLocation W43133058571 @default.
• W4313305857 hasRelatedWork W1980409408 @default.
• W4313305857 hasRelatedWork W2012279509 @default.
• W4313305857 hasRelatedWork W2021393753 @default.
• W4313305857 hasRelatedWork W2047967234 @default.
• W4313305857 hasRelatedWork W2064236298 @default.
• W4313305857 hasRelatedWork W2439875401 @default.
• W4313305857 hasRelatedWork W2748952813 @default.
• W4313305857 hasRelatedWork W2899084033 @default.
• W4313305857 hasRelatedWork W4256109032 @default.
• W4313305857 hasRelatedWork W4313305857 @default.

• next